| April 19,
2007
Washington Post
Breast Cancer Drop Tied To Less Hormone
Use
By Rob Stein
New federal statistics provide powerful
evidence that the sharp drop in hormone use by menopausal women
that began in 2002 caused a dramatic decline in breast cancer cases,
according to an analysis being published today.
The statistics show that the number of breast cancer cases being
diagnosed began falling abruptly after concerns emerged about the
safety of hormone treatment and that the decrease persisted into
the following year, strengthening the case that the trends are related,
researchers said.
"At first I didn't believe it -- it was so astounding,"
said Donald A. Berry of the University of Texas, who led the analysis
published in the New England Journal of Medicine. "But it really
looks like it's a story that holds together."
The researchers estimated from the findings that about 16,000 fewer
cases of breast cancer are being diagnosed each year because of
the decrease in hormone use, a stunning reversal of a decades-long
increase in cases.
"This is colossal," said Rowan Chlebowski of Harbor-UCLA
Medical Center, who helped conduct the analysis. "It translates
into thousands of fewer breast cancers that have been diagnosed
in women in the United States and could be in the future."
The findings also help explain one of the biggest mysteries about
breast cancer -- why the number of cases rose steadily for decades.
Increasing hormone use probably played a key role, along with better
detection by mammography and other factors, several experts said.
"I think this solves at least part of the mystery," Berry
said.
Others said the findings underscore the danger of drug therapies
becoming widely used before they have been thoroughly tested.
"An awful lot of breast cancer was caused by doctors' prescriptions,"
said Larry Norton of Memorial Sloan-Kettering Cancer Center in New
York. "That's a very serious and sobering thought."
Norton and others said the findings should encourage more women
to stop hormone use altogether or to continue at the lowest dose
and for the shortest time necessary. The findings come as another
study involving nearly 1 million British women found that hormones
also increase the risk of ovarian cancer.
"These data add to the message that we really should be discouraging
women from initiating menopausal hormones," said Marcia L.
Stefanick of Stanford University. "We need to stop underplaying
those risks. They are very real."
Some researchers, however, questioned the findings, saying the
drop in breast cancer occurred too soon to have been caused by the
decline in hormone use.
"Even if there was a cause and effect, you wouldn't expect
it to show up for five or 10 years," said Hugh Taylor of Yale
University. "It just doesn't fit with what we know about the
basic biology of breast cancer."
Wyeth Pharmaceuticals, which makes the most widely prescribed hormones,
also questioned the link, saying hormone use continued to fall while
the breast cancer rate remained stable after the initial drop. The
researchers, they said, had failed to rule out other causes, such
as a decline in mammogram use.
"We do respectfully disagree with the conclusion here,"
said Joseph Camardo, Wyeth's senior vice president of global medical
affairs.
Millions of women took hormones for years to alleviate hot flashes
and other symptoms of menopause. Some also viewed hormones as a
virtual fountain of youth -- boosting energy, preventing wrinkles
and providing health benefits, including reducing the risk of heart
disease.
In 2002, however, the large federal Women's Health Initiative study
stunned doctors and patients when it showed that the hormones not
only failed to protect women's hearts, they appeared to increase
the risk of heart attacks and strokes, as well as breast cancer
and other health problems. The news prompted millions of women to
abandon the drugs.
Researchers first reported last year that the breast cancer rate
had dropped in 2003 after rising steadily since the 1980s, and that
the drop appeared to coincide with the news about hormones. Experts
have been waiting for the latest federal data, from 2004, to see
if the trend persisted.
The new analysis showed that the breast cancer rate began falling
almost immediately after the Women's Health Initiative findings
were released in July 2002, dropping 6.7 percent between 2002 and
2003. The 2004 data showed that the rate remained at the lower level,
having fallen 8.6 percent between 2001 and 2004.
The researchers said that indicates the drop was primarily caused
by the decrease in hormone use and not other factors, such as fewer
women having mammograms, greater use of hormone-blocking drugs such
as tamoxifen or an unknown change in the environment, and that it
will be long-lasting.
"The fact that the incidence rate did not go back up suggests
that the effects will be long-lived," said Peter Ravdin of
the University of Texas, who helped conduct the analysis.
The link is strengthened by the fact that the decline occurred
primarily in women ages 50 to 69, the age group most likely to use
hormones, and predominantly in a form of breast cancer sensitive
to estrogen. New cases of this type fell 14.7 percent, the researchers
said.
The researchers and others emphasized that further research will
be needed to determine whether the reduction in diagnoses will translate
into fewer deaths.
Researchers suspect hormone use may spur the growth of tumors that
may never become life-threatening. Without hormone use, the tumors
may remain small enough to never be detected by mammograms. They
may even shrink.
"Think of a cancer that you are feeding with hormones and
now you stop the fuel. What's going to happen to it?" Berry
said. "Most likely it stops growing and stays under the radar,
or maybe even regresses. It could even disappear."
|